Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M652Revenue $M5.2Net Margin (%)-2,445.0Altman Z-Score12.0
Enterprise Value $M347EPS $-1.3Operating Margin %-2,480.2Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-2,445.0Higher ROA y-yY
Price/Book2.110-y EBITDA Growth Rate %--Quick Ratio13.1Cash flow > EarningsY
Price/Sales1215-y EBITDA Growth Rate %--Current Ratio13.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-38.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-42.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M98.7ROIC % (ttm)-879.7Gross Margin Increase y-yN

Gurus Latest Trades with CLDX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CLDXJoel Greenblatt 2015-06-30 Sold Out -0.01%$23.67 - $30.1
($26.5)
$ 6.61-75%Sold Out0
CLDXJoel Greenblatt 2015-03-31 Buy 0.01%$18.29 - $31.78
($23.85)
$ 6.61-72%New holding35,223
CLDXFirst Eagle Investment 2014-12-31 Add0.01%$12.55 - $20.93
($16.61)
$ 6.61-60%Add 123.82%559,542
CLDXFirst Eagle Investment 2014-09-30 Buy 0.01%$12.05 - $17.57
($14.51)
$ 6.61-54%New holding250,000
CLDXFirst Eagle Investment 2014-03-31 Sold Out -0.01%$16.95 - $31.59
($25.6)
$ 6.61-74%Sold Out0
CLDXFirst Eagle Investment 2013-12-31 Reduce-0.04%$21.51 - $36.71
($25.51)
$ 6.61-74%Reduce -75.45%135,000
CLDXFirst Eagle Investment 2013-06-30 Reduce-0.02%$11.01 - $16.09
($13.13)
$ 6.61-50%Reduce -45.89%665,560
CLDXGeorge Soros 2012-06-30 Sold Out -0.06%$3.9 - $5.26
($4.39)
$ 6.6151%Sold Out0
CLDXFirst Eagle Investment 2012-06-30 Add0.02%$3.9 - $5.26
($4.39)
$ 6.6151%Add 260.87%1,660,000
CLDXGeorge Soros 2012-03-31 Buy 0.06%$2.77 - $5.46
($4)
$ 6.6165%New holding803,200
CLDXFirst Eagle Investment 2012-03-31 Add0.01%$2.77 - $5.46
($4)
$ 6.6165%Add 360.00%460,000
CLDXFirst Eagle Investment 2011-12-31 Reduce$2.11 - $3.21
($2.7)
$ 6.61145%Reduce -71.43%100,000
CLDXFirst Eagle Investment 2011-06-30 Buy 0.01%$3.03 - $4.46
($3.75)
$ 6.6176%New holding350,000
CLDXFirst Eagle Investment 2010-03-31 Sold Out $4.35 - $6.39
($4.93)
$ 6.6134%Sold Out0
CLDXFirst Eagle Investment 2009-12-31 Buy $4.2 - $5.66
($4.78)
$ 6.6138%New holding100,000
CLDXFirst Eagle Investment 2009-09-30 Sold Out $4.95 - $7.93
($6.35)
$ 6.614%Sold Out0
CLDXFirst Eagle Investment 2009-06-30 Buy $6.81 - $11.22
($8.56)
$ 6.61-23%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CLDX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CLDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CATLIN AVERY WSr. VP & CFO 2015-11-23Sell25,000$18-64.17view
ELLBERGER LARRYDirector 2015-08-25Buy5,000$14-53.93view
ELLBERGER LARRYDirector 2015-08-20Buy5,000$15-57view
ELLBERGER LARRYDirector 2015-08-18Buy5,000$15.95-59.56view
ELLBERGER LARRYDirector 2015-08-13Buy5,000$16.59-61.12view
Marucci Anthony SPresident and CEO 2015-08-13Buy5,800$16.81-61.63view
CATLIN AVERY WSr. VP & CFO 2015-06-15Sell25,000$24.59-73.77view
van den Broek RichardDirector 2014-12-17Sell0$0-73.77view
LIPTON KAREN SHOOSDirector 2013-12-06Sell17,728$24.5-73.67view
PENNER HARRY JRDirector 2013-12-06Sell17,728$24.5-73.67view

Quarterly/Annual Reports about CLDX:

    News about CLDX:

    Articles On GuruFocus.com
    Cantor Fitzgerald and Brean Capital Positive on Celldex Therapeutics Following Positive Data For Bra Jun 01 2015 
    Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
    Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
    Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
    CLDX up 223%, Cohen Gains Big Apr 23 2013 
    Steve Cohen Increases Celldex Up 145% Apr 06 2013 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
    Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
    CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 

    More From Other Websites
    Celldex Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference Feb 04 2016
    Why traders are buying puts in Celldex Jan 28 2016
    Celldex Nears Pivotal Decision Point for Brain Tumor Therapy Jan 28 2016
    Equities Updates on Biotechnology -- Celldex Therapeutics, Amgen, Exelixis, and Ariad Pharma Jan 27 2016
    Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : January 5, 2016 Jan 05 2016
    Where Investors Are Going - Analyst Review of Linn Energy, Celldex Therapeutics, Party City Holdco... Dec 29 2015
    Top Cowen Health Care and Biotech Best Idea Stock Picks for 2016 Dec 17 2015
    Here is What Hedge Funds Think About Celldex Therapeutics, Inc. (CLDX) Dec 14 2015
    Cancer Immunotherapy ETF Offers High Growth Investing Potential Dec 14 2015
    Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : December 14,... Dec 14 2015
    CELLDEX THERAPEUTICS, INC. Financials Dec 08 2015
    Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Atezolizumab in... Dec 08 2015
    Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Atezolizumab in... Dec 08 2015
    Celldex Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 07 2015
    Long-term Survival Benefit Demonstrated in Phase 2 ReACT Study of RINTEGA(R) in Recurrent... Nov 20 2015
    Celldex Presents Varlilumab Mechanism Data at SITC Annual Meeting 2015 Nov 06 2015
    Celldex Reports Third Quarter 2015 Results Nov 05 2015
    Celldex reports 2Q loss Aug 10 2015
    Celldex Reports Second Quarter 2015 Results Aug 10 2015
    Celldex to Report Second Quarter 2015 Financial Results and Host Corporate 2015 Objectives Update... Aug 04 2015
    Celldex Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference Jul 02 2015
    Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer Jul 01 2015
    Independent Data Safety and Monitoring Board Recommends Continuation of Celldex's Phase 3 Study of... Jun 29 2015
    Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma... May 31 2015
    Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in... May 28 2015
    Celldex Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference May 27 2015
    Celldex Therapeutics to Present Data from the ReACT Study at 2015 ASCO Annual Meeting May 13 2015
    Celldex Reports First Quarter 2015 Results Apr 29 2015
    Celldex reports 1Q loss Apr 29 2015
    Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in... Apr 20 2015
    Celldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer... Apr 06 2015
    Celldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with... Apr 06 2015
    Celldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination... Mar 17 2015
    Celldex Therapeutics Announces Upcoming Presentation at the Cowen and Company 35th Annual Health... Mar 03 2015
    Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares Feb 28 2015
    Celldex reports 4Q loss Feb 24 2015
    Celldex tops Street 3Q forecasts Nov 05 2014

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK